title: [Efficacy analysis of sequential surgery after the DCF scheme induction chemotherapy in T2-3 laryngeal carcinoma and hypopharyngeal carcinoma].
abstract: OBJECTIVE
  To study clinical efficacy of surgery after the DCF induction chemotherapy in T2-3 laryngeal carcinoma and hypopharyngeal carcinoma.
  
  
  METHODS
  To analyze clinical data about 102 cases of T2-3 laryngeal carcinoma and hypopharyngeal carcinoma retrospectively, 62 cases were divided into experimental group and 40 cases in control group, the experimental group completed three cycles of the DCF induction chemotherapy, then the efficacy was evaluated, surgery were carried out in the end, the control group received operation directly. In two groups, tumor response rates, toxicities, positive surgical margin rates and survival rate differences were observed and compared.
  
  
  RESULTS
  Tumor response rate was 61.3% in experimental group, the laryngeal carcinoma rate was significantly lower than that in hypopharyngeal (44.4% VS 84.6%, P < 0.05). Compared to its control, there were no significant differences about the positive surgical margin rate, the median survival time, 3-year and 5-year survival rate of laryngeal carcinoma(P > 0.05). The foci edges of 0. 3 cm and 0. 5 cm positive margin rate of hypopharyngeal carcinoma in experimental group were significantly lower than in its control (P < 0.05), but among the 1 cm edge' positive rate, the median survival time, 3-year and 5-year survival rate no significant differences were found (P > 0.05). During induction chemotherapy in the experimental group, no serious adverse reactions were found.
  
  
  CONCLUSIONS
  Induction chemotherapy of DCF regimen can not only narrow T2-3 laryngeal carcinoma and hypopharyngeal carcinoma' area, but also ensure an adequate safety margin.
authors.forename: Guangping
authors.initials: G
authors.lastname: Lu
authors.forename: Jiqun
authors.initials: J
authors.lastname: Pan
authors.forename: Zhibiao
authors.initials: Z
authors.lastname: Liu
mesh_terms: D003131:Combined Modality Therapy; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D060828:Induction Chemotherapy; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D012189:Retrospective Studies; D015996:Survival Rate